Thiti Susiriwatananont

Bangkok, 10330, Thailand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Prognostic Significance, Predictive Value, and Emerging Directions for Clinical Implementation.

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Prognostic Significance, Predictive Value, and Emerging Directions for Clinical Implementation.

Journal: Cancers

Published: April 02, 2026

The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma.

The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 22, 2025

Feasibility and Preliminary Effectiveness of the ChulaCancer Mobile Chatbot for Supportive Care of Patients With Breast or Colorectal Cancer Receiving Chemotherapy: Pilot Randomized Controlled Trial.

Feasibility and Preliminary Effectiveness of the ChulaCancer Mobile Chatbot for Supportive Care of Patients With Breast or Colorectal Cancer Receiving Chemotherapy: Pilot Randomized Controlled Trial.

Journal: JMIR formative research

Published: November 20, 2025

The Gut Microbiome as a Biomarker and Therapeutic Target of Immune Checkpoint Inhibitors: A Review for Oncologists.

The Gut Microbiome as a Biomarker and Therapeutic Target of Immune Checkpoint Inhibitors: A Review for Oncologists.

Journal: Cells

Published: October 18, 2025

Clinical Outcomes of HER2-Low Versus HER2-Zero in HR-Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study.

Clinical Outcomes of HER2-Low Versus HER2-Zero in HR-Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study.

Journal: International journal of breast cancer

Published: July 22, 2025

Long-term impact of anthracycline in early-stage breast cancer, bridging of MiRNAs profiler for early cardiotoxicity.

Long-term impact of anthracycline in early-stage breast cancer, bridging of MiRNAs profiler for early cardiotoxicity.

Journal: Cardio-oncology (London, England)

Published: January 17, 2025

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand.

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand.

Journal: BMC cancer

Published: June 21, 2024

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac.

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac.

Journal: Vaccines

Published: January 11, 2023

Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment.

Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment.

Journal: Vaccines

Published: August 16, 2022

Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine.

Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine.

Journal: Vaccines

Published: August 13, 2022

Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls.

Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls.

Journal: Human vaccines & immunotherapeutics

Published: July 01, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026